Recruiting NCT07286656
A Study of GensSci098 in Subjects With Graves' Disease
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: GenSci098.
- Who it may be relevant to
- Registry conditions: Safety, Tolerability, GenSci098, Graves Disease. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Subcutaneous Dose of GenSci098 in Patients With Graves' Disease
Overview
To evaluate the safety and tolerability of single ascending subcutaneous doses of GenSci098 in patients with Graves' Disease
Interventions
- Drug GenSci098
* Administration: Only one dose of GenSci098 will be given. * Route of Administration: Subcutaneous (injected under the skin). * Dose Levels: • Dose 1 • Dose 2• Dose 3• Dose 4
Primary outcome measures
- Incidence and severity of adverse events (AEs) (physical examination, vital signs, laboratory tests, 12-lead electrocardiogram [ECG]). [Time frame: 141 days]
Eligibility criteria
Inclusion criteria
- Age ≥ 18 years.
- Voluntary signed informed consent.
- Confirmed diagnosis of diffuse toxic goiter (Graves' disease).
- Abnormal thyroid function tests (e.g., elevated T4, and suppressed TSH).
- No prior or recent use of antithyroid medications (discontinued for at least 4 weeks).
- Female participants must be postmenopausal, surgically sterile, or using a highly effective method of contraception.
- Male participants must agree to practice abstinence, use a highly effective method of contraception， or have undergone vasectomy.
- Ability to comply with the follow-up schedule and understand and adhere to the study requirements.
Exclusion criteria
- Non-diffuse toxic goiter-induced hyperthyroidism.
- Previous radioactive iodine treatment or thyroid surgery.
- History or risk of thyroid storm.
- Use of thyroid hormone medications within the past 6 weeks.
- accompanied by active thyroid eye disease.
- Thyroid eye disease treated with radiation/surgery,or need for urgent surgery surgical or medical intervention.
- Optic nerve lesions or corneal damage.
- Use of steroids or immunosuppressants within the past 3 months,or those who have used biologics within 6 months
- Inability to quit smoking during the study.
- Allergy to the study drug or monoclonal antibodies.
- Participation in another clinical trial within the past 3 months.
- Abnormal electrocardiogram.
- Significant hepatic or renal dysfunction.
- Pregnancy,breastfeeding,or positive pregnancy test.
- Positive for HIV,syphilis,hepatitis B,or hepatitis C.
- History of drug or substance abuse.
- Other autoimmune diseases requiring treatment.
- History of malignant tumors.
- Splenectomy or major surgery within the past 6 months.
- Severe cardiovascular,pulmonary,hepatic,renal,neurological,or hematological diseases.
- Other conditions deemed unsuitable by investigators.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- N/A
- Model
- Sequential
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
China · 1 center
- The First Affiliated Hospital of China Medical University — Shenyang
Identifiers
NCT: NCT07286656 · GenSci098-102